Catalog No.
RHE82902
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
IF: 1:50-1:200, IHC: 1:100-1:200, ChIP: 1:20-1:50, WB: 1:1000-1:5000
Target
Protein brahma homolog 1, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4, Protein BRG-1, Transcription activator BRG1, BRG1-associated factor 190A, SNF2-beta, SNF2L4, SMARCA4, ATP-dependent helicase SMARCA4, SNF2B, BRG1, BAF190A, Mitotic growth and transcription activator
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P51532
Applications
IF, IHC, ChIP, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R1Y25
SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review., PMID:40313929
Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma., PMID:40278919
Discovery of mutations predictive of survival benefit from immunotherapy in first-line NSCLC: A retrospective machine learning study of IMpower150 liquid biopsy data., PMID:40043417
Immunohistochemical analysis of 147 cases of low-grade endometrial stromal sarcoma: refining the immunohistochemical profile of LG-ESS on a large, molecularly confirmed series., PMID:39836188
Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4-UT Without PD-L1 Expression: A Case Report and Review of Literature., PMID:39648153
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors., PMID:39637943
Marked Response to Nivolumab by a Patient With SMARCA4-Deficient Undifferentiated Urothelial Carcinoma Showing High PD-L1 Expression: A Case Report., PMID:38923369
Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report., PMID:38881888
Myoepithelial tumors of soft tissue and bone in children and young adults: A clinicopathologic study of 40 cases occurring in patients ≤ 21 Years of age., PMID:38782103
PD-1 antibody in combination with chemotherapy for the treatment of SMARCA4-deficient advanced undifferentiated carcinoma of the duodenum: Two case reports., PMID:38576599
An aggressive case of a thoracic undifferentiated SMARCA4-deficient tumor with extensive pleural involvement., PMID:38390699
Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report., PMID:38348622
An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies., PMID:37927802
Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer., PMID:37715852
Brain and Spinal Cord Tumors of Embryonic Origin., PMID:37452947
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial., PMID:37429302
Unusual Aspects of Small Cell Carcinoma of the Ovary of Hypercalcaemic Type: Retained SMARCA4 Immunohistochemical Staining and Positive Staining With TLE1., PMID:37345679
Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab., PMID:37051241
Characterization of Switch/Sucrose Nonfermenting Complex Proteins and Nestin Expression in a Cohort of Pediatric Central Nervous System Tumors., PMID:37036408
Malignant undifferentiated and rhabdoid tumors of the gastroesophageal junction and esophagus with SMARCA4 loss: a case series., PMID:36549598
Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type., PMID:35903699
Trans-activation of eotaxin-1 by Brg1 contributes to liver regeneration., PMID:35614068
Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features., PMID:35468657
Brg1 Supports B Cell Proliferation and Germinal Center Formation Through Enhancer Activation., PMID:34539636
Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients., PMID:34440689
NUT carcinoma of the lung., PMID:34176698
Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma., PMID:34095712
Small Cell Carcinoma of the Ovary, Hypercalcemic Type, in a 12-Month-Old Girl., PMID:34047234
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma., PMID:34030451
Diagnostic Immunohistochemistry of Soft Tissue and Bone Tumors: An Update on Biomarkers That Correlate with Molecular Alterations., PMID:33921435
Sox2-Evf2 lncRNA-mediated mechanisms of chromosome topological control in developing forebrain., PMID:33593819
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)., PMID:33405951
SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature., PMID:33367658
PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab., PMID:33246647
Response to 'Is the case really a SMARCA4-deficient thoracic sarcoma?'., PMID:33210422
Is the case really a SMARCA4-deficient thoracic sarcoma?, PMID:33075212
Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report., PMID:32363992
SWI/SNF protein and claudin-4 expression in anaplastic carcinomas arising in mucinous tumours of the ovary and retroperitoneum., PMID:32268438
Recombination may occur in the absence of transcription in the immunoglobulin heavy chain recombination centre., PMID:32086526
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma., PMID:31906887
Sinonasal Undifferentiated Carcinoma (SNUC): From an Entity to Morphologic Pattern and Back Again-A Historical Perspective., PMID:31876536
Dramatic increase in gene mutational burden after transformation of follicular lymphoma into TdT+ B-lymphoblastic leukemia/lymphoma., PMID:31776129
Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report., PMID:31617320
Assessment of the genes and molecular mechanisms of B cells activation through systems biology approaches., PMID:31524152
Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor., PMID:31114851
Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report., PMID:30972962
Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas., PMID:30474823
Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas., PMID:30188361
SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients., PMID:29689242
An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm., PMID:29520069
For research use only. Not for human or drug use.
